(0.92%) 5 064.46 points
(0.89%) 38 240 points
(1.47%) 15 834 points
(0.15%) $79.12
(6.00%) $2.05
(0.19%) $2 315.40
(0.64%) $26.92
(1.09%) $965.35
(-0.09%) $0.932
(-0.39%) $10.99
(-0.10%) $0.798
(-1.38%) $91.97
5 days till quarter result
(bmo 2024-05-07)
Expected move: +/- 10.31%
@ $2.49
Išleistas: 13 vas. 2024 @ 22:29
Grąža: 0.00%
Ankstesnis signalas: vas. 13 - 16:30
Ankstesnis signalas:
Grąža: 0.81 %
Live Chart Being Loaded With Signals
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration...
Stats | |
---|---|
Šios dienos apimtis | 1.00M |
Vidutinė apimtis | 2.26M |
Rinkos kapitalizacija | 374.32M |
EPS | $0 ( 2024-03-12 ) |
Kita pelno data | ( $-0.0800 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.11 |
ATR14 | $0.00700 (0.28%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-19 | Duarte Ira | Buy | 3 874 | Common Stock |
2024-04-19 | Duarte Ira | Sell | 1 122 | Common Stock |
2024-04-19 | Duarte Ira | Sell | 3 874 | Restricted Stock Units |
2024-04-19 | Forbes William P | Buy | 3 874 | Common Stock |
2024-04-19 | Forbes William P | Sell | 3 874 | Restricted Stock Units |
INSIDER POWER |
---|
66.42 |
Last 96 transactions |
Buy: 15 032 989 | Sell: 3 241 807 |
Tūris Koreliacija
Heron Therapeutics Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
TTGT | 0.894 |
TFFP | 0.891 |
RMRM | 0.888 |
VSTA | 0.884 |
TLGT | 0.881 |
ARVN | 0.881 |
BIOL | 0.88 |
GAINL | 0.875 |
PAIC | 0.875 |
WISA | 0.875 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
BOCH | -0.901 |
NETE | -0.9 |
AMRB | -0.894 |
MMAC | -0.888 |
SHSP | -0.886 |
VLYPO | -0.877 |
SEDG | -0.866 |
IBEX | -0.864 |
SLGN | -0.856 |
RNLC | -0.854 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Heron Therapeutics Inc Koreliacija - Valiuta/Žaliavos
Heron Therapeutics Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $127.04M |
Bruto pelnas: | $61.94M (48.75 %) |
EPS: | $-0.800 |
FY | 2023 |
Pajamos: | $127.04M |
Bruto pelnas: | $61.94M (48.75 %) |
EPS: | $-0.800 |
FY | 2022 |
Pajamos: | $107.67M |
Bruto pelnas: | $52.80M (49.04 %) |
EPS: | $-1.240 |
FY | 2021 |
Pajamos: | $87.18M |
Bruto pelnas: | $41.16M (47.21 %) |
EPS: | $-2.24 |
Financial Reports:
No articles found.
Heron Therapeutics Inc
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.